ICML 2025 | Unmet needs & challenges that remain when treating patients with EBV+ PTLD
Sylvain Choquet, MD, APHP, Paris, France, highlights the challenges of treating patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV+ PTLD), emphasizing the need for more diverse cell matches. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We still have some unmet needs in this situation. The effect of tab-cel is only in 50% of patients, so we need other kinds of treatment. The other thing is we do not have cells for every kind of people. We have to match with at least one HLA1 and one HLA2. So for example, for people from Asia, it’s difficult to find some cells. And so we need more improvements on more cells to deal with the entire population of the world for this kind of patients...
We still have some unmet needs in this situation. The effect of tab-cel is only in 50% of patients, so we need other kinds of treatment. The other thing is we do not have cells for every kind of people. We have to match with at least one HLA1 and one HLA2. So for example, for people from Asia, it’s difficult to find some cells. And so we need more improvements on more cells to deal with the entire population of the world for this kind of patients. If it does not work, if you do not have any cells, you can try, if the patient is still solid positive, to use brentuximab vedotin that could work also pretty well in 50% of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
